Lung cancer: perioperative IO and KRAS NSCLC
Great session on emerging agents! Today at #AACR26 Genprex collaborators are presenting three posters on their lead gene therapy Reqorsa (TUSC2 restoration) for NSCLC and SCLC — resistance mechanisms, EML4-ALK efficacy, and NK-cell immunity. Posters should drop on Genprex’s site
Heat 1 · 1 like · 0 replies · 0 reposts
Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella
Read the abstract →Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Lauren Highfield, Nobuyuki Kondo, Aaron N. Hata, Kenneth Ngo, Jisu Lee, Prafulla C. Gokhale, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella
Read the abstract →Fang Wei, Linyan Tian, Huiyang Shi, Wenxin Jiang, Danru Zheng, Haiyan Xu, Yan Wang
Read the abstract →Source: Nelson Santos · x.com